Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid- In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2023	$ 397,273	$ 7	$ 1,119,976	$ (1,271)	$ (721,439)
Beginning balance (in shares) at Dec. 31, 2023		74,350
Issuance of pre-funded warrants to purchase common stock, net of offering costs	122,726		122,726
Issuance of common stock, net of offering costs	23,088	$ 1	23,087
Issuance of common stock, net of offering costs, (in shares)		1,377
Share-based compensation expense	8,512		8,512
Issuance of common stock under equity plans	2,555		2,555
Issuance of common stock under equity plans (in shares)		454
Other comprehensive income (loss)	455			455
Net loss	(49,525)				(49,525)
Ending balance at Mar. 31, 2024	505,084	$ 8	1,276,856	(816)	(770,964)
Ending balance (in shares) at Mar. 31, 2024		76,181
Beginning balance at Dec. 31, 2023	397,273	$ 7	1,119,976	(1,271)	(721,439)
Beginning balance (in shares) at Dec. 31, 2023		74,350
Net loss	(154,766)
Ending balance at Sep. 30, 2024	423,771	$ 8	1,298,852	1,116	(876,205)
Ending balance (in shares) at Sep. 30, 2024		77,749
Beginning balance at Mar. 31, 2024	505,084	$ 8	1,276,856	(816)	(770,964)
Beginning balance (in shares) at Mar. 31, 2024		76,181
Share-based compensation expense	8,430		8,430
Issuance of common stock under equity plans	3,040		3,040
Issuance of common stock under equity plans (in shares)		241
Other comprehensive income (loss)	353			353
Net loss	(50,837)				(50,837)
Ending balance at Jun. 30, 2024	466,070	$ 8	1,288,326	(463)	(821,801)
Ending balance (in shares) at Jun. 30, 2024		76,422
Share-based compensation expense	8,324		8,324
Issuance of common stock under equity plans	2,202		2,202
Issuance of common stock under equity plans (in shares)		327
Exercise of pre-funded warrants (in shares)		1,000
Other comprehensive income (loss)	1,579			1,579
Net loss	(54,404)				(54,404)
Ending balance at Sep. 30, 2024	423,771	$ 8	1,298,852	1,116	(876,205)
Ending balance (in shares) at Sep. 30, 2024		77,749
Beginning balance at Dec. 31, 2024	413,640	$ 8	1,308,290	764	(895,422)
Beginning balance (in shares) at Dec. 31, 2024		78,229
Share-based compensation expense	7,842		7,842
Issuance of common stock under equity plans	143		143
Issuance of common stock under equity plans (in shares)		375
Exercise of pre-funded warrants (in shares)		2,174
Other comprehensive income (loss)	210			210
Net loss	(57,429)				(57,429)
Ending balance at Mar. 31, 2025	364,406	$ 8	1,316,275	974	(952,851)
Ending balance (in shares) at Mar. 31, 2025		80,778
Beginning balance at Dec. 31, 2024	413,640	$ 8	1,308,290	764	(895,422)
Beginning balance (in shares) at Dec. 31, 2024		78,229
Net loss	(197,667)
Ending balance at Sep. 30, 2025	242,542	$ 9	1,334,704	918	(1,093,089)
Ending balance (in shares) at Sep. 30, 2025		87,016
Beginning balance at Mar. 31, 2025	364,406	$ 8	1,316,275	974	(952,851)
Beginning balance (in shares) at Mar. 31, 2025		80,778
Share-based compensation expense	6,949		6,949
Issuance of common stock under equity plans	515		515
Issuance of common stock under equity plans (in shares)		101
Exercise of pre-funded warrants	1	$ 1
Exercise of pre-funded warrants (in shares)		5,918
Other comprehensive income (loss)	(263)			(263)
Net loss	(66,122)				(66,122)
Ending balance at Jun. 30, 2025	305,486	$ 9	1,323,739	711	(1,018,973)
Ending balance (in shares) at Jun. 30, 2025		86,797
Share-based compensation expense	10,965		10,965
Issuance of common stock under equity plans (in shares)		219
Other comprehensive income (loss)	207			207
Net loss	(74,116)				(74,116)
Ending balance at Sep. 30, 2025	$ 242,542	$ 9	$ 1,334,704	$ 918	$ (1,093,089)
Ending balance (in shares) at Sep. 30, 2025		87,016

Kura Oncology, Inc. 10-Q